Wenwen Mao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenwen Mao has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Kunmei Liu
Department of Hematology, The Third Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publication - Liefen Yin
Department of Hematology, the Second Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publication - Lilan Wang
Department of Chest Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publication - Ling Yang
Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650031, China
1 shared publication - Xuezhong Gu
Department of Hematology, The First People Hospital in Yunnan Province, Kunming, China
1 shared publication - Yunchao Huang
Department of Thoracic and Cardiovascular Surgery, The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, China.
1 shared publication
Latest Publications
- Open Access
- 23 July 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-12
Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis
This meta-analysis was performed to explore the impact of minimal residual disease (MRD) prior to transplantation on the prognosis for patients with acute lymphoblastic leukemia (ALL). A systematic search of PubMed, Embase, and the Cochrane Library was conducted for relevant studies from database inception to March 2016. A total of 21 studies were included. Patients with positive MRD prior to allogeneic stem cell transplantation (allo-SCT) had a significantly higher rate of relapse compared with those with negative MRD (HR = 3.26; P < 0.05). Pre-transplantation positive MRD was a significant negative predictor of relapse-free survival (RFS) (HR = 2.53; P < 0.05), event-free survival (EFS) (HR = 4.77; P < 0.05), and overall survival (OS) (HR = 1.98; P < 0.05). However, positive MRD prior to transplantation was not associated with a higher rate of nonrelapse mortality. Positive MRD before allo-SCT was a predictor of poor prognosis after transplantation in ALL. Not applicable.
- 23 July 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-12
Open AccessInfluence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis
This meta-analysis was performed to explore the impact of minimal residual disease (MRD) prior to transplantation on the prognosis for patients with acute lymphoblastic leukemia (ALL). A systematic search of PubMed, Embase, and the Cochrane Library was conducted for relevant studies from database inception to March 2016. A total of 21 studies were included. Patients with positive MRD prior to allogeneic stem cell transplantation (allo-SCT) had a significantly higher rate of relapse compared with those with negative MRD (HR = 3.26; P < 0.05). Pre-transplantation positive MRD was a significant negative predictor of relapse-free survival (RFS) (HR = 2.53; P < 0.05), event-free survival (EFS) (HR = 4.77; P < 0.05), and overall survival (OS) (HR = 1.98; P < 0.05). However, positive MRD prior to transplantation was not associated with a higher rate of nonrelapse mortality. Positive MRD before allo-SCT was a predictor of poor prognosis after transplantation in ALL. Not applicable.